Monashee Investment Management LLC Reduces Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Monashee Investment Management LLC reduced its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 10.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 448,164 shares of the company’s stock after selling 51,836 shares during the period. Monashee Investment Management LLC’s holdings in Compass Therapeutics were worth $650,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of CMPX. Rock Springs Capital Management LP increased its stake in Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after purchasing an additional 150,336 shares in the last quarter. Blue Owl Capital Holdings LP grew its holdings in shares of Compass Therapeutics by 2.6% during the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after buying an additional 75,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Compass Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 2,334,171 shares of the company’s stock valued at $3,386,000 after acquiring an additional 24,393 shares during the period. SG Americas Securities LLC raised its stake in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Compass Therapeutics by 25.2% during the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock worth $404,000 after acquiring an additional 56,000 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Compass Therapeutics

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 28.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. D. Boral Capital reissued a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Monday. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 1st. Jefferies Financial Group raised their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Finally, Guggenheim restated a “buy” rating on shares of Compass Therapeutics in a research report on Tuesday, April 22nd. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Trading Down 3.2 %

Shares of CMPX opened at $1.84 on Wednesday. The stock’s 50 day moving average is $2.17 and its two-hundred day moving average is $2.10. Compass Therapeutics, Inc. has a 12 month low of $0.77 and a 12 month high of $4.08. The firm has a market cap of $254.44 million, a P/E ratio of -4.97 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities research analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.